<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>6,11-<z:chebi fb="0" ids="29362">Ethano</z:chebi>-12,12-diaryl-6,11-dihydrobenzo[b]<z:chebi fb="0" ids="36646">quinolizinium</z:chebi> <z:chebi fb="36" ids="36916">cations</z:chebi> 8, a novel class of <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>) <z:chebi fb="68" ids="48706">antagonists</z:chebi> acting at the phencyclidine site, have been identified </plain></SENT>
<SENT sid="1" pm="."><plain>Structure-activity relationship studies around the lead compound 8a led to the identification of 12g (WIN 67870-2), one of the most potent compounds in this series </plain></SENT>
<SENT sid="2" pm="."><plain>Compound 12g has a Ki = 1.8 +/- 0.2 nM vs [3H]TCP binding, has 700-fold selectivity for binding to the open state of the <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor-<z:chebi fb="0" ids="24869">ionophore</z:chebi>, and was devoid of MK-801- and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCP</z:e>-like behavioral effects in rats </plain></SENT>
<SENT sid="3" pm="."><plain>Compound 12g was neuroprotective in cultured mouse cortical neurons and exhibited antiischemic activity in a rat middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>/reperfusion model of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>